KeyNeurotek Pharmaceuticals Opens New Research Facilities in Leipzig
As part of the expansion of its business activities, KeyNeurotek Pharma GmbH, a subsidiary of Magdeburg-based KeyNeurotek Pharmaceuticals AG, has opened laboratory space and offices at Leipzig's BIO CITY center in order to further expand its existing network to research institutions in Leipzig. The research and development activities in Leipzig will focus on several preclinical projects as well as clinical development activities in the area of urinary incontinence. At present, the company is preparing a Phase-IIa proof-of-concept study of its KN203 product candidate, a µ-opioid receptor agonist acting on bladder muscle contraction. The clinical testing of KN203 is expected to start in 2009 immediately after regulatory approval and will include 180 patients suffering from urinary incontinence or an overactive bladder.
At the same time, all CNS-related development activities of KeyNeurotek Pharmaceuticals AG will be expanded at the company's Magdeburg site. KeyNeurotek's lead product KN38-7271, a dual cannabinoid CB1/CB2 receptor agonist, is currently investigated in a multinational Phase-IIa-study in comatose TBI patients to prove its clinical safety and tolerability. Furthermore, KeyNeurotek Pharmaceuticals is hoping for therapeutic efficacy signals. Study results are expected this summer. KN38-7271 has been granted Orphan Drug Designation by the European authorities.
Dr. Frank Striggow, CEO of KeyNeurotek Pharmaceuticals AG, said: Setting up the business activities of KeyNeurotek Pharma GmbH in Leipzig is an important milestone for KeyNeurotek. Moreover, the new facilities reflect our strong relationships with the excellent research cluster in the Middle Germany region."
KeyNeurotek Pharmaceuticals AG
KeyNeurotek Pharmaceuticals, a privately held biotechnology company, was founded in 2000 within the Magdeburg, Germany, region, one of the leading centers of neuroscience in Europe.
The company pursues a number of drug candidates in various preclinical and clinical stages. The most advanced compound, KN38-7271, a cannabinoid receptor agonist, is in a Phase IIa trial in comatose patients with traumatic brain injury. At present, there is no targeted therapy for these patients.
KeyNeurotek Pharmaceuticals has unique functional and tissue-based high throughput screening platforms for compatible ex vivo and in vivo studies (TELOMICSTM). Based on its know-how, KeyNeurotek develops innovative therapies for the treatment of various neurodegenerative diseases of the central nervous system, such as traumatic brain injury (TBI), stroke, Alzheimer's disease and urinary incontinence/overactive bladder. The company has built a strong network with renowned local and international partners, including, among others, the Leibniz Association, the Max Planck Society and Fraunhofer Society, Evotec, Schwarz Pharma/UCB, Bayer Schering and Gruenenthal. KeyNeurotek Pharmaceuticals has been awarded the Hugo-Junckers-Innovation Award of the State of Sachsen-Anhalt in 2002 and 2004 and the Innovation Award of the German Industry in 2006.